News Breaks |
|
|
| January 4, 2013 |
| 07:08 EDT |  | ENMD | EntreMed announces initiation of second site for Phase 2 trial of ENMD-2076
EntreMed announced the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer. The primary objective of this Phase 2 trial is to assess clinical benefits of ENMD-2076 in TNBC patients. In addition, it will also test in a clinical setting the correlation between patient responses to ENMD-2076 and p-53 based genomic profiling predictive biomarker. |
|
|
News For ENMD From The Last 14 Days Check below for free stories on ENMD the last two weeks. |
|
|
| There are no results for ENMD |
|
|
|
|
